Contents

Search

colestipol (Colestid)

Tradename: Colestid. Indications: 1) treatment of hypercholesterolemia & elevated LDL cholesterol 2) treatment of relapsing colitis due to C difficile 3) relief from pruritus associated with increased amounts of bile acids 4) treatment of digitalis toxicity [6] Tabs: 1 g: start 2 g PO QD/BID, max 16 g/day Granules: 1) start 5 g PO QD/BID, max 30 g/day 2) mix in cold liquids (juice at least 90 mL) 3) stir until completely mixed 4) medication will not dissolve Granules: 500 g (450 g {flavored}) Packets: 5 g, 7.5 g (orange) Pharmacokinetics: colestipol is not absorbed Adverse effects: 1) common (> 10%) - constipation 2) less common (1-10%) - abdominal pain & distension, belching, flatulence, nausea/vomiting, diarrhea 3) uncommon (< 1%) - peptic ulceration, GI irritation & bleeding, cholecystitis, cholelithiasis, dermatitis, urticaria, joint pain, arthritis, headache, dizziness, anxiety, vertigo, drowsiness, anorexia, fatigue, weakness, shortness of breath, increased serum phosphorous & serum chloride, decreased serum Na+ & serum K+ 4) other [2] - increased levels of triglycerides Drug interactions: 1) interferes with absorption of many medications 2) take other medications 1 hour before or 4-6 hours after colestipol Mechanism of action: 1) depletes bile acid pool 2) removes plasma LDL cholesterol 3) upregulates hepatic LDL receptors

Interactions

drug interactions drug adverse effects of anti-hyperlipidemic agents monitor with bile acid sequestrants

Related

cholesterol Clostridium difficile; Clostridioides difficile low density lipoprotein (LDL, beta-lipoprotein)

General

bile acid sequestrant

Properties

MISC-INFO: elimination route FECES pregnancy-category ? safety in lactation ?

Database Correlations

PUBCHEM correlations

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998 Department of Veterans Affairs, VA National Formulary
  3. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 354
  4. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  5. Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  6. Deprecated Reference